为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

吉非替尼 (ZD1839), 表皮生长因子受体 erbB1 抑制剂

选择性EGFR酪氨酸激酶抑制剂
规格或纯度: ≥99%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
G125799-50mg
50mg 期货 Stock Image
G125799-250mg
250mg 现货 Stock Image
G125799-1g
1g 现货 Stock Image
G125799-5g
5g 现货 Stock Image
G125799-10g
10g 现货 Stock Image
G125799-25g
25g 现货 Stock Image
G125799-100g
100g 现货 Stock Image

基本描述

别名 吉非替尼
英文别名 ZD 1839|AM20090619|Gefitinib [USAN:INN:BAN]|SY017890|CHEBI:49668|nchembio866-comp14|4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline|4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-|GEFITINI
规格或纯度 ≥99%
英文名称 Gefitinib (ZD1839)
生化机理 Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and has been shown to increase phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) in HaCaT cells. Studies sμggest that gefitinib can enhance keratinocyte apoptosis via an EGFR-independent JNK-activation pathway. Research indicates that gefitinib can induce apoptosis in several cell lines including, HaCaT cells, KG-1, P39, and primary CD34+ myeloblasts.Orally active, potent, selective EGFR (Epidermal growth factor receptor) tyrosine kinase inhibitor (IC 50 = 33 nM). Inhibits EGF-stimulated EGFR autophosphorylation and inhibits tumor growth in vivo . Enhances efficacy of cytotoxic agents.
储存温度 2-8°C储存
运输条件 冰袋运输
备注 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。
产品介绍

Gefitinib (ZD1839)是一种EGFR抑制剂,作用于NR6wtEGFR和NR6W细胞中的Tyr1173,Tyr992,Tyr1173和Tyr992,IC50 分别为37 nM,37nM,26 nM和57 nM。An EGFR-tyrosine kinase inhibitor

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
An EGFR-tyrosine kinase inhibitor

产品属性

ALogP 4.1

名称和标识符

IUPAC Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
INCHI InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChi Key XGALLCVXEZPNRQ-UHFFFAOYSA-N
Canonical SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Isomeric SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
PubChem CID 123631
分子量 446.9

化学和物理性质

溶解性 Soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).
敏感性 对热敏感
比旋光度 1.62
沸点 586.8 °C
熔点 194.0 to 198.0 °C

安全和危险性(GHS)

象形图
ghs08

Health Hazard

ghs09

Environmental Hazard

ghs05

Corrosive

ghs07

Harmful

信号词 Danger
危险声明 H315: Causes skin irritation
H351: Suspected of causing cancer
H373: Causes damage to organs through prolonged or repeated exposure
H411: Toxic to aquatic life with long lasting effects
H302: Harmful if swallowed
H318: Causes serious eye damage
H400: Very toxic to aquatic life
H361: Suspected of damaging fertility or the unborn child
预防措施声明 P273,P280,P302+P352,P321,P405,P501,P264,P260,P270,P362+P364,P391,P330,P203,P264+P265,P301+P317,P305+P354+P338,P318,P317,P332+P317,P319

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH.  (2002)  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy..  Cancer Res,  62  (20):  (5749-54).  [PMID:12384534]
2. Gan CJ et al..  (2020)  EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation..  Biochem Biophys Rep,  22  ():  (100763).  [PMID:32322693]
3. Yan J et al..  (2020)  GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma..  Am J Cancer Res,  10  (11):  (3705-3720).  [PMID:33294262]
4. Devaraj V & Bose B.  (2019)  Morphological State Transition Dynamics in EGF-Induced Epithelial to Mesenchymal Transition..  J Clin Med,  (7):  ().  [PMID:31247884]
5. Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Shuo Liu, Mengjun Hou, Yaling Long & Xuansheng Ding.  (2023)  Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.  Pharmaceutical Biology,  (61):  (33-41).  [PMID:38100532]